Tag: Amal Therapeutics
Boehringer Ingelheim acquires Swiss biotech Amal Therapeutics
Amal’s lead vaccine ATP128 is currently being developed for stage IV colorectal cancer and is slated to begin its first-in-human trials later this month.
